An observational study in Brain Tumor Adult, Brain Metastases From Solid Tumors and Brain Tumor, Primary, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of California, San Francisco · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Brain Neoplasms by University of California, San Francisco — 4 open to participants now, 4 under way, none of them phase 3. Brain Neoplasms · University of California, San Francisco.
Among the 14 studies in Brain Neoplasms by University of California, San Francisco, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 13th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →4 of the 14 studies in Brain Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 13 across the 11 interventional studies, 1,709 across the 3 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
1 of the studies in Brain Neoplasms by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05435859University of California, San FranciscoFunctional Organization of the Superior Temporal Gyrus for Speech Perception | 2027-07-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Brain Neoplasms by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
PRIMARY OBJECTIVES:
SECONDARY OBJECTIVES:
1. Measure patient-reported quality of life changes pre- and post-radiotherapy using a standard University of California, San Francisco (UCSF) -approved questionnaire.
OUTLINE:
This is a single-arm, non-randomized, open-label pilot study. Participants will be study duration spans 12 months post-brain radiotherapy.
Adult participants with brain cancers receiving care at University of California, San Francisco (UCSF)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study entails longitudinal assessment of plasma biomarkers (Aβ, GFAP, phospho Tau, NfL), determination of APOE genotype, neuropsychiatric testing Brain Health Assessment test (BHA), a clinically validated neurocognitive battery compiling metrics on memory and language), and brain morphometric measurements synchronized with standard of care brain MRIs.
Procedure: Blood sample · Procedure: Brain magnetic resonance imaging (MRI) · Procedure: Brain Health Assessment · Radiation: Quality of Life (QoL) Questionnaire
Blood sample will be collected
Brain MRI will be performed during the course of data collection
Brain Health Assessment will be performed during the course of data collection
QoL questionnaire will be given to participants during the course of data collection
Mean change in serum Amyloid-beta peptide (Aβ)
Mean change in biomarker for Aβ over time will be reported
Time frame: Up to 6 months
Mean change in serum Amyloid-beta peptide (Aβ) by APOE genotype
Mean change in biomarker for Aβ by APOE genotype over time will be reported
Time frame: Up to 6 months
Mean change of score on the European Organization for Research and Treatment of Cancer quality of life questionnaire - Brain Module (EORTC-QLQ-BN20)
The EORTC QLQ-BN20 consists of 20 questions; seven single item symptom scales (headaches, seizures, drowsiness, hair loss, itchy skin, leg weakness and bladder control), along with four multi-item scales (future uncertainty, visual disorder, motor dysfunction and communication deficit). Raw scores for the QLQ-BN20 items are computed by calculating the mean of the items in each subscale, or the item for each individual and linearly transform the scores to a 0-100 scale. A higher score represents worse QOL for all QLQ-BN20 scales and single items.
Time frame: Up to 18 months from date of first radiation dose
Mean change in serum Glial Fibrillary Acidic Protein (GFAP)
Mean change in biomarker for GFAP over time will be reported
Time frame: Up to 6 months
Mean change in serum Glial Fibrillary Acidic Protein (GFAP) by APOE genotype
Mean change in biomarker for GFAP by APOE genotype over time will be reported
Time frame: Up to 6 months
Mean change in serum Phosphorylated TAU (p-TAU)
Mean change in biomarker for p-TAU over time will be reported
Time frame: Up to 6 months
Mean change in serum Phosphorylated TAU (p-TAU) by APOE genotype
Mean change in biomarker for p-TAU by APOE genotype over time will be reported
Time frame: Up to 6 months
Mean change in serum Neurofilament Light Chain (NfL)
Mean change in biomarker for NfL over time will be reported
Time frame: Up to 6 months
Mean change in serum Neurofilament Light Chain (NfL) by APOE genotype
Mean change in biomarker for NfL by APOE genotype over time will be reported
Time frame: Up to 6 months
Mean change in Brain Health Assessment by APOE genotype
Mean change in of Brain Health Assessment by APOE genotype over time will be reported
Time frame: Up to 6 months
Mean change in Hippocampal Volume
Mean change in Hippocampal Volume as measured by MRI over time will be reported
Time frame: Up to 6 months
Mean change in Hippocampal Volume by APOE genotype
Mean change in Hippocampal Volume as measured by MRI by APOE genotype over time will be reported
Time frame: Up to 6 months
Change in scores on the European Organization for Research and Treatment of Cancer quality of life questionnaire 30 (EORTC-QLQ-C30) over time
The functional domains measure the quality of life in Physical functioning, Role functioning, Emotional functioning, Cognitive functioning, Social functioning. Scores consists of responses to items with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the items that make up each domains with a resulting total range of 1 - 4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the functional domains represents a high level of functioning.
Time frame: Up to 18 months from date of first radiation dose
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Feb 2029, 27 months after the start.
Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 27 months is below that.
Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.
Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 16, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Feb 2029, on Oct 15, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Dec 2028 → Aug 2029, last on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →